CytomX Therapeutics
CTMX
CTMX
119 hedge funds and large institutions have $637M invested in CytomX Therapeutics in 2017 Q4 according to their latest regulatory filings, with 34 funds opening new positions, 47 increasing their positions, 24 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
119
Holders Change
+22
Holders Change %
+22.68%
% of All Funds
2.7%
Holding in Top 10
2
Holding in Top 10 Change
+1
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
34
Increased
47
Reduced
24
Closed
12
Calls
$21K
Puts
$50K
Net Calls
-$29K
Net Calls Change
-$29K
Top Buyers
| 1 |
PA
Perceptive Advisors
New York
|
$52.6M |
| 2 |
BlackRock
New York
|
$55.9M |
| 3 |
PAMU
Pictet Asset Management (UK)
London,
United Kingdom
|
$12.4M |
| 4 |
Invesco
Atlanta,
Georgia
|
$10.8M |
| 5 |
State Street
Boston,
Massachusetts
|
$23M |
| Name | Holding | Trade Value |
Shares Change |
Shares Change % |
|
|---|---|---|---|---|---|
|
VF
126
Virtu Financial
New York
| – | -$223K | -12,291 | Closed |
|
|
DCM
127
DAFNA Capital Management
Los Angeles,
California
| – | -$107K | -5,900 | Closed |
|
128
Acadian Asset Management
Boston,
Massachusetts
| – | -$29K | -1,608 | Closed |
|
|
TRCT
129
Tower Research Capital (TRC)
New York
| – | -$28K | -1,508 | Closed |
|
130
Simplex Trading
Chicago,
Illinois
| – | -$5K | -290 | Closed |
|
|
TWA
131
TCI Wealth Advisors
Tucson,
Arizona
| – | -$2K | -100 | Closed |
|